MGI(SH:688114) Jin Rong Jie·2026-02-01 11:22Core Viewpoint - The acquisition of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. by BGI Genomics is a strategic move to enhance its capabilities in the fields of spatial omics and nanopore sequencing, positioning the company as a leader in the global life sciences sector with a comprehensive product matrix covering "full-length sequencing + spatial omics" [1][2][3]. Group 1: Acquisition Details - BGI Genomics plans to acquire 100% equity of both companies for a total consideration of approximately 366 million yuan [1]. - The acquisition will allow BGI Genomics to integrate cutting-edge technologies into its operations, enhancing its product offerings and market position [2][3]. Group 2: Technological Integration - The acquisition will create a seamless technology chain combining short-read (DNBSEQ), long-read (CycloneSEQ), and spatial omics (Stereo-seq) technologies, making BGI Genomics the only company globally to cover these three advanced technologies [2][3]. - Stereo-seq technology is recognized for its international leadership in resolution and field of view, with applications in neuroscience, regenerative medicine, and tumor microenvironment analysis [2][3]. - CycloneSEQ technology offers unique advantages such as long-read, real-time sequencing, and portability, effectively addressing challenges in large genome assembly and clinical testing [2][3]. Group 3: Strategic Advantages - The acquisition strengthens BGI Genomics' first-mover advantage in the AI medical field, enhancing its "AI + gene sequencing" strategy and supporting the development of intelligent laboratory automation [4]. - The integration of these technologies will enable BGI Genomics to provide comprehensive services from library construction to sequencing and data analysis, significantly improving customer service capabilities and retention [3]. Group 4: Financial Considerations - The acquisition is strategically timed to capitalize on the valuation window during the target companies' incubation phase, allowing BGI Genomics to acquire assets at a more realistic value [5]. - The estimated equity value of Huada Sanjian is 158 million yuan, while Huada Xufeng is valued at 207.7 million yuan, both assessed using the income method [5]. - Performance guarantees from the sellers include commitments for cumulative net profits of at least 50.1 million yuan for Huada Sanjian and 82.8 million yuan for Huada Xufeng over specified periods, with cash compensation provisions in case of unmet targets [6]. Group 5: Market Impact - The acquisition is expected to significantly enhance BGI Genomics' revenue scale and profitability, leveraging its global sales network to promote the new technologies [6]. - The integration of new revenue streams from spatial omics and nanopore sequencing will contribute to the company's long-term growth and industry influence [6]. - The transaction aligns with the broader trend of deep mergers and acquisitions in the industry, reflecting a focus on strategic integration and value creation [6].